GSK3 inhibition drives maturation of NK cells and enhances their antitumor activity

Cancer Research

Volumn 77, Issue 20, 2017, Pages 5664-5675

  Cichocki, Frank ^a   Valamehr, Bahram ^b   Bjordahl, Ryan ^b   Zhang, Bin ^a   Rezner, Betsy ^b   Rogers, Paul ^b   Gaidarova, Svetlana ^b   Moreno, Stacey ^b   Tuininga, Katie ^a   Dougherty, Phillip ^a   McCullar, Valarie ^a   Howard, Peter ^a   Sarhan, Dhifaf ^a   Taras, Emily ^a   Schlums, Heinrich ^c   Abbot, Stewart ^b   Shoemaker, Daniel ^b   Bryceson, Yenan T ^c   Blazar, Bruce R ^a   Wolchko, Scott ^b   Cooley, Sarah ^a   Miller, Jeffrey S ^a   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b Fate Therapeutics Inc   (United States)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD57 ANTIGEN; GAMMA INTERFERON; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN 15; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR T BET; TRANSCRIPTION FACTOR ZEB2; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; 6 [[2 [[4 (2,4 DICHLOROPHENYL) 5 (4 METHYL 1H IMIDAZOL 2 YL) 2 PYRIMIDINYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; ENZYME INHIBITOR; PYRIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL MATURATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NATURAL KILLER CELL; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; A-549 CELL LINE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; DRUG SCREENING; ENZYMOLOGY; IMMUNOLOGY; K-562 CELL LINE; NONOBESE DIABETIC MOUSE; OVARIAN NEOPLASMS; PROCEDURES; TUMOR CELL LINE;

A549 CELLS; ANIMALS; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; GLYCOGEN SYNTHASE KINASE 3; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-15; K562 CELLS; KILLER CELLS, NATURAL; MICE; MICE, INBRED NOD; OVARIAN NEOPLASMS; PYRIDINES; PYRIMIDINES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85031433592     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-0799     Document Type: Article

References (31)

1. Bryceson YT, March ME, Ljunggren HG, Long EO. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 2006;107:159–66.
2. Biassoni R, Cantoni C, Falco M, Verdiani S, Bottino C, Vitale M, et al. The human leukocyte antigen (HLA)-C-specific "activatory" or "inhibitory" natural killer cell receptors display highly homologous extracellular domains but differ in their transmembrane and intracytoplasmic portions. J Exp Med 1996;183:645–50.
3. Anfossi N, André P, Guia S, Falk CS, Roetynck S, Stewart CA, et al. Human NK cell education by inhibitory receptors for MHC class I. Immunity 2006;25:331–42.
4. Braud VM, Allan DS, O'Callaghan CA, Söderström K, D'Andrea A, Ogg GS, et al. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C. Nature 1998;391:795–9.
5. Le Dréan E, Vély F, Olcese L, Cambiaggi A, Guia S, Krystal G, et al. Inhibition of antigen-induced T cell responses and antibody-induced NK cell cytotoxicity by NKG2A: association of NKG2A with SHP-1 and SHP-2 protein-tyrosine phosphatases. Eur J Immunol 1998;28:264–76.
6. Lanier LL, Corliss B, Wu J, Phillips JH. Association of DAP12 with activating CD94/NKG2C NK cell receptors. Immunity 1998;8:693–701.
7. Nagler A, Lanier LL, Cwirla S, Phillips JH. Comparative studies of human FcRIII-positive and negative natural killer cells. J Immunol 1989;143: 3183–91.
8. Lanier LL, Le AM, Phillips JH, Warner NL, Babcock GF. Subpopulations of human natural killer cells defined by expression of the Leu-7 (HNK-1) and Leu-11 (NK-15) antigens. J Immunol 1983;131:1789–96.
9. Tilden AB, Grossi CE, Itoh K, Cloud GA, Dougherty PA, Balch CM. Subpopulation analysis of human granular lymphocytes: associations with age, gender and cytotoxic activity. Nat Immun Cell Growth Regul 1986; 5:90–99.
10. Lopez-Vergès S, Milush JM, Schwartz BS, Pando MJ, Jarjoura J, York VA, et al. Expansion of a unique CD57+NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc Natl Acad Sci U S A 2011;108:14725–32.
11. Abo T, Miller CA, Balch CM. Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults. Eur J Immunol 1984;14:616–23.
12. Nielsen CM, White MJ, Goodier MR, Riley EM. Functional significance of CD57 expression on human NK cells and relevance to disease. Front Immunol 2013;4:422.
13. Sun JC, Beilke JN, Lanier LL. Adaptive immune features of natural killer cells. Nature 2009;457:557–61.
14. Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, et al. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. Immunity 2015; 42:443–56.
15. Lopez-Vergès S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010;116:3865–74.
16. Björkström NK, Riese P, Heuts F, Andersson S, Fauriat C, Ivarsson MA, et al. Expression patters of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education. Blood 2010; 116:3853–64.
17. Brady J, Hayakawa Y, Smyth MJ, Nutt SL. IL-21 induces the functional maturation of murine NK cells. J Immunol 2004;172:2048–58.
18. Beurel E, Grieco SF, Jope RS. Glycogen synthase kinase-3 (GSK3): regulation, actions, and diseases. Pharmacol Ther 2015;148:114–31.
19. Schroeder JH, Bell LS, Janas ML, Turner M. Pharmacological inhibition of glycogen synthase kinase 3 regulates T cell development in vitro. PLoS One 2013;8:e58501.
20. Taylor A, Harker JA, Chanthong K, Stevenson PG, Zuniga EI, Rudd CE. Glycogen synthase kinase 3 inactivation drives T-bet-mediated downregulation of receptor PD-1 to enhance CD8(+) cytolytic T cell responses. Immunity 2016;44:274–86.
21. Cichocki F, Miller JS. In vitro development of human Killer-Immunoglobulin Receptor-positive NK cells. Methods Mol Biol 2010; 612:15–26.
22. Miller JS, Klingsporn S, Lund J, Perry EH, Verfaillie C, McGlave P. Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy. Bone Marrow Transplant 1994;14:555–62.
23. Murray JT, Campbell DG, Morrice N, Auld GC, Shpiro N, Marquez R, et al. Exploitation of KESTREL to identify NDRG family members as physiological substrates for SGK1 and GSK3. Biochem J 2004;384:477–88.
24. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitor: a further update. Biochem J 2007;408:297–315.
25. Sullivan BM, Juedes A, Szabo SJ, von Herrath M, Glimcher LH. Antigen-driven effector CD8 T cell function regulated by T-bet. Proc Natl Acad Sci U S A 2003;100:15818–23.
26. Townsend MJ, Weinmann AS, Matsuda JL, Salomon R, Farnham PJ, Biron CA, et al. T-bet regulates the terminal maturation and homeostasis of NK and Valpha14i NKT cells. Immunity 2004;20:477–94.
27. Van Helden MJ, Goossens S, Daussy C, Mathieu AL, Faure F, Marçais A, et al. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. J Exp Med 2015; 212:2015–25.
28. Kallies A, Carotta S, Huntington ND, Bernard NJ, Tarlinton DM, Smyth MJ, et al. A role for Blimp1 in the transcriptional network controlling natural killer cell maturation. Blood 2011;117:1869–79.
29. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8þ T cell function by the transcription factor Eomesodermin. Science 2003;302:1041–3.
30. Cichocki F, Cooley S, Davis Z, DeFor TE, Schlums H, Zhang B, et al. CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT. Leukemia 2016;30:456–63.
31. Gordon SM, Chaix J, Rupp LJ, Wu J, Madera S, Sun JC, et al. The transcription factors T-bet and Eomes control key checkpoints of natural killer cell maturation. Immunity 2012;36:55–67.